High-mobility group B1 (HMGB1) and receptor for advanced glycation end-products (RAGE) expression in canine lymphoma

Anticancer Res. 2010 Dec;30(12):5043-8.

Abstract

Background: Canine lymphoma is a commonly occurring, spontaneously developing neoplasia similar to human non-Hodgkin's lymphoma and, thus, is used as a valuable model for human malignancy. HMGB1 and RAGE are strongly associated with tumour progression and vascularisation. Consequently, deregulated RAGE and HMGB1 may play an important role in the mechanisms involved in lymphoma progression.

Materials and methods: Expression patterns of HMGB1 and RAGE were analysed in 22 canine lymphoma and three canine non-neoplastic control samples via real time PCR and canine beta-glucuronidase gene (GUSB) as endogenous control.

Results: HMGB1 was up-regulated in the neoplastic samples, while RAGE expression remained inconspicuous.

Conclusion: This study demonstrated similar mechanisms in lymphoma progression in humans and dogs due to overexpression of HMGB1, which was described in human lymphomas. RAGE remained stable in terms of expression indicating that the extracellular HMGB1-induced effects are regulated by HMGB1 itself.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Disease Models, Animal
  • Dogs
  • Gene Expression Regulation, Neoplastic
  • HMGB1 Protein / biosynthesis*
  • HMGB1 Protein / genetics
  • Lymphoma / genetics
  • Lymphoma / metabolism*
  • Lymphoma / pathology
  • Receptor for Advanced Glycation End Products
  • Receptors, Immunologic / biosynthesis*
  • Receptors, Immunologic / genetics
  • Reverse Transcriptase Polymerase Chain Reaction

Substances

  • HMGB1 Protein
  • Receptor for Advanced Glycation End Products
  • Receptors, Immunologic